Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temodal in Progressive Low Grade Gliomas
NCT00003466Phase 2Completed
- Sponsor
- Duke University
- Start
- Mar 1998
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in glioma, sponsored by Duke University. Primary endpoints: Response Rate and Activity of Temozolomide. Started Mar 1998; status: completed.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00003466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003466.